- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Ultrasound BI-RADS might need some fine-tuning
Breast cancers missed by mammography could have been misclassified as benign lesions by ultrasound to begin with, according to a study presented at the American Institute of Ultrasound in Medicine meeting in Orlando in June.
Breast cancers missed by mammography could have been misclassified as benign lesions by ultrasound to begin with, according to a study presented at the American Institute of Ultrasound in Medicine meeting in Orlando in June.
Dr. Dona J. Hills and colleagues from the Queens-Long Island Medical Group in New York found that 41 cancers matched current BI-RADS 2 and 3 assignments, based on their original ultrasound descriptions. They also found that 23 of the 41 had benign or negative findings on mammography. Physicians should be suspicious about ultrasound-detected lesions with atypical features, which can cause false negatives in mammography as well, Hills said.
"If we exclude suspicious findings from the 'probably benign' category and put them into a BI-RADS 4, we might not be underestimating as many cancers as we had underestimated before," she said.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
